Clinics and data-backed medicinal cannabis firm Emyria has embarked on a drug-development program of its own. Here, chief executive Dr Michael Winlo tells Cannabiz that TGA registration must be the ambition for producers, and suggests why some may be unwilling to invest in research.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Developing and registering its own drugs was not part of Emyria’s business plan.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...